Non-Hodgkin lymphoma includes more than 60 distinct cancers that start in the lymph system. Some forms grow slowly and may require no immediate treatment, while others are aggressive and need urgent chemotherapy. Treatment has improved dramatically with targeted therapies and immunotherapies that harness the immune system.
What's actually going on in research
Trials are testing CAR T-cell therapies for more lymphoma types, bispecific antibodies that redirect immune cells to kill cancer, combinations with BTK inhibitors for certain subtypes, and chemotherapy-free regimens. Researchers are studying how to avoid or delay chemotherapy in slow-growing forms and how to cure aggressive lymphomas that return after initial treatment.
CAR T-cell therapy expansion
After initial approval for relapsed lymphoma, CAR T is moving into earlier treatment lines and new subtypes. Trials are testing whether using it sooner leads to better long-term outcomes than waiting until multiple relapses.
Bispecific antibodies
Drugs like glofitamab and epcoritamab link immune T cells directly to lymphoma cells, creating an immediate attack without modifying cells outside the body. These are being tested as alternatives to CAR T and in combination with other treatments.
Chemotherapy-free regimens
Several trials combine targeted drugs like BTK inhibitors with antibodies to avoid traditional chemotherapy entirely. Early results suggest some people with certain lymphoma types can achieve remission without chemo's side effects.
What to know before you search
Eligibility depends on lymphoma subtype, number of prior treatments, how well those treatments worked, overall health, and sometimes specific genetic markers in the cancer.
What types of trials are currently open
- CAR T trials — Testing modified immune cells that attack lymphoma, either as earlier treatment or for new lymphoma subtypes.
- Bispecific antibody trials — Testing drugs that bridge immune cells to lymphoma cells, often given as injections or infusions.
- Targeted therapy trials — Testing pills like BTK inhibitors, PI3K inhibitors, or other drugs that block specific cancer growth signals.
- Combination trials — Testing whether adding new drugs to standard chemotherapy or combining targeted therapies improves outcomes.
- Maintenance trials — Testing whether continuing treatment after remission prevents lymphoma from returning.
Recently added Non-hodgkin Lymphoma trials
Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment With TP53-Mutated Large B-Cell Lymphoma (LBCL)
This is a study for patients with a type of blood cancer called large B-cell lymphoma (LBCL) who have a mutation in a gene called TP53. This gene mutation often makes the cancer harder to treat with standard therapies. CAR T-cell therapy is a treatment that uses a patient's own immune cells to fight cancer. However, some patients relapse (the cancer comes back) after CAR T-cell therapy. This study will test whether taking two drugs - chidamide (a tablet taken by mouth) and a PD-1 inhibitor (given by intravenous infusion) - as maintenance therapy after CAR T-cell therapy can help keep the cancer from coming back. Participants in this study will receive CAR T-cell therapy, followed by maintenance treatment with chidamide combined with a PD-1 inhibitor. Doctors will closely monitor participants for how well the treatment works and for any side effects. The study will take place at a single hospital, and all participants will receive the same treatment. The main goal of the study is to find out if this maintenance treatment is effective and safe for patients with TP53-mutant large B-cell lymphoma.
Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)
This is a multi-center phase 1 open-label study to determine the safety of ABL001 and INO in patients with relapsed or refractory Philadelphia chromosome-positive b-cell acute lymphoblastic leukemia.
Find Non-hodgkin Lymphoma trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.